hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06321185 id: 2024/177 briefTitle: Laparoscopic Cholecystectomy and Quality of Recovery overallStatus: RECRUITING date: 2024-03-25 date: 2024-08-25 date: 2024-08-25 date: 2024-03-20 date: 2024-03-27 name: Istanbul University class: OTHER briefSummary: This clinical trial aims to compare the Quality of Recovery-15 (QoR-15) scale scores in three groups of patients undergoing laparoscopic cholecystectomy. The first group will be applied subcostal transversus abdominis plane (subcostal TAP) block, the second group will receive local anesthetic infiltration into port sites, and the third group will receive only IV analgesics. conditions: Laparoscopic Cholecystectomy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The patients will be allocated randomly into three groups. Two groups will receive subcostal TAP block or port site local anesthetic infiltration, and the third group will not receive any intervention. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: The subcostal TAP block and port-site infiltration will be applied after the patient has general anesthesia, so the patient will not know the allocated group. The healthcare providers who work in the ward and are responsible for the analgesic treatments will be blinded to the patient's group. The outcomes assessor who will question the QoR-15 scale at the 24th hour will also be blinded. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 150 type: ESTIMATED name: Subcostal TAP block name: Port site local anesthetic infiltration name: No intervention or local anesthetic administration measure: Quality of Recovery-15 (QoR-15) scale measure: Postoperative rescue analgesic requirement measure: Consumption of postoperative opioid analgesics measure: Numerical Rating Scale (NRS) scores measure: Postoperative nausea and vomiting sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istanbul University Istanbul Medical Faculty, Department of Anesthesiology and Reanimation status: RECRUITING city: Istanbul state: Fatih zip: 34093 country: Turkey name: Muserref B Dincer role: CONTACT phone: +905321624712 email: mberildincer@gmail.com name: Ahmet K Koltka role: CONTACT email: koltkak@yahoo.com name: Muserref B Dincer role: PRINCIPAL_INVESTIGATOR lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06321172 id: 785 briefTitle: Muscle and Bone Changes After 6 Months of FES Cycling acronym: FES-Bike overallStatus: ACTIVE_NOT_RECRUITING date: 2022-09-09 date: 2024-01-22 date: 2024-04-29 date: 2024-03-20 date: 2024-03-22 name: IRCCS Eugenio Medea class: OTHER name: Politecnico di Milano name: Villa Beretta Rehabilitation Center name: National Research Council briefSummary: The goal of this clinical trial is to assess the effectiveness of FES cycling in terms of changes morpho-functional characteristics of the leg muscles, training performance and bone trophism in 5 subjects with Spinal Cord Injury after 6 months of training. The main question\[s\] it aims to answer are:
Participants will train for 6 months with FES-cycling twice a week. Each session includes at most 30 minutes of stimulation. conditions: Spinal Cord Injuries studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 5 type: ACTUAL name: FES Bike measure: Changes in the morpho-functional characteristics of the thigh muscles of the dominant limb measure: Changes in the morpho-functional characteristics of the thigh muscles of the dominant limb measure: Changes in the morpho-functional characteristics of the thigh muscles of the dominant limb measure: Changes in bone quality measure: Changes in data referring to the vegetative nervous system measure: Changes in data referring to the vegetative nervous system measure: Changes in data referring to the vegetative nervous system measure: Changes in the intestinal function measure: Changes in the intestinal function measure: Changes in the intestinal function measure: Changes in the level of spasticity of the lower limbs measure: Changes in the level of spasticity of the lower limbs measure: Changes in the level of spasticity of the lower limbs measure: Changes in the level of pain perceived measure: Changes in the level of pain perceived measure: Changes in the level of pain perceived measure: Changes in the General Well Being of the pilots while training measure: Changes in the General Well Being of the pilots while training measure: Changes in the General Well Being of the pilots while training measure: Pilots' motivation in carrying out a sporting activity measure: Pilots' motivation in carrying out a sporting activity sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Scientific Institute, IRCCS E. Medea city: Bosisio Parini state: Lecco zip: 23842 country: Italy lat: 45.80075 lon: 9.29 hasResults: False
nctId: NCT06321159 id: Nursing Dep. briefTitle: Investigation of the Effect of Mobile Software Use in Blood Pressure Management of Hypertensive Individuals on Quality of Life and Disease Self-Efficacy overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2024-11-30 date: 2026-01-30 date: 2024-03-20 date: 2024-03-20 name: Inonu University class: OTHER briefSummary: Hypertension is a prevalent health concern, affecting one in three adults globally, with the potential to lead to fatal complications. However, an alarming proportion of those diagnosed-four out of five individuals-struggle to effectively manage this condition. As such, the effective management of hypertension becomes paramount. A study conducted post-earthquake by a principal investigator and a scholarship recipient revealed that 47.9% of participants received a hypertension diagnosis, and a significant 67.8% ceased active management of the condition. Existing literature suggests a notable decline in the quality of life among individuals unable to manage hypertension effectively. While current research emphasizes the components of nutrition, exercise, and medication adherence in hypertension management, the integration of these components into mobile applications is notably lacking. This project seeks to enhance disease management for users by integrating crucial elements, including blood pressure measurement, into a user-friendly mobile application, thereby providing a distinctive contribution. The proposed application encompasses the recording of vital signs, integration of customized diet and exercise programs tailored for hypertension, and provision of consultancy services for identifying deviations in health status and implementing appropriate interventions. The integration of these components is anticipated to contribute to preventing or minimizing potential complications for the patient. Comprehensive studies incorporating such an approach are rarely encountered in the existing literature, enhancing the originality of this research. The project\&#39;s overarching goal is to enable individuals to manage hypertension even in extraordinary circumstances, such as earthquakes. Consequently, the study will assess how the mobile application influences individuals\&#39; quality of life and disease self-efficacy.
Conducted between April 2024 and January 2026, the project adopts a pre-test post-test control group experimental design in the four most earthquake-affected provinces. It involves 614 individuals diagnosed with hypertension, residing in temporary living space in Malatya, Hatay, Kahramanmaraş, and Adıyaman, with 78, 77, and 74 participants in Malatya, Hatay, and Adıyaman, respectively. Data collection tools include the Personal Identification Information Form, Hypertension Self-Efficacy Scale, SF-36 Quality of Life Scale, and International Physical Activity Scale-Short Form, administered through face-to-face interviews. The mobile application development will be a collaborative effort with two faculty members from the Department of Computer Engineering and expert academicians. For the diet program within the application, eight questions will be used to uncover individuals\&#39; dietary preferences. Calculations based on Body Mass Index, basal metabolic rate, and daily energy requirements will inform the diet program, which will encompass five food groups and their caloric values. Notifications about diet adherence will be sent for each meal. In the exercise program, individuals will measure and record blood pressure and medication intake. Those with a blood pressure of 140/90 mmHg or higher will be included based on expert physician recommendations, with notifications for those exceeding 160/100 mmHg to consult a physician. A personalized exercise program will be created based on the OMRİ-RİS scale, supported by animations. Training videos for blood pressure measurements and medication adherence will be recorded and supervised by local academic nurse practitioners. Data analysis will utilize appropriate statistical tests conducted through computer programs. The project is anticipated to contribute significantly to researcher development, enhance quality of life and disease management, increase productivity, and establish new projects. conditions: Hypertension, Essential Hypertension studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Our study has two groups of 78 participants each. Our study is an experimental study with pretest-posttest control group. primaryPurpose: OTHER masking: SINGLE maskingDescription: Participants will be determined blindly by being assigned by a site. whoMasked: PARTICIPANT count: 614 type: ESTIMATED name: mobile application measure: SF- 36 Life Quality Scale measure: Hypertension Self-Efficacy Scale measure: International Physical Activity Scale-Short Form sex: ALL minimumAge: 30 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06321146 id: LY2024-029-B briefTitle: Evaluation of EEG Power Spectrum in Patients With Traumatic Coma acronym: EPIC overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-04-30 date: 2026-04-30 date: 2024-03-20 date: 2024-03-20 name: RenJi Hospital class: OTHER name: Beijing Tiantan Hospital name: Xiangya Hospital of Central South University name: The General Hospital of Eastern Theater Command name: Anhui No.2 Provincial People's Hospital briefSummary: Development of objective, reliable, and convenient assessment methods of disorders of consciousness is crucial. We aim to conduct multicenter prospective observational study and non-invasively collect EEG from patients with traumatic coma to analyze the sequential characteristics of EEG power spectrum, and explore their prognostic value for consciousness recovery. conditions: Coma conditions: Brain Injuries, Traumatic studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 210 type: ESTIMATED measure: EEG power spectrum measure: Coma Recovery Scale-Revised (CRS-R) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Anhui No.2 Provincial People's Hospital city: Hefei state: Anhui country: China name: Yongming Zhang, Dr. role: CONTACT lat: 31.86389 lon: 117.28083 facility: Beijing Tiantan Hospital, Capital Medical University city: Beijing state: Beijing country: China name: Guoyi Gao, Dr. role: CONTACT lat: 39.9075 lon: 116.39723 facility: Xiangya Hospital, Central South University city: Changsha state: Hunan country: China name: Jinfang Liu, Dr. role: CONTACT lat: 28.19874 lon: 112.97087 facility: The General Hospital of Eastern Theater Command city: Nanjing state: Jiangsu country: China name: Chiyuan Ma, Dr. role: CONTACT lat: 32.06167 lon: 118.77778 facility: Brain Injury Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University city: Shanghai state: Shanghai zip: 201114 country: China name: Junfeng Feng role: CONTACT phone: +8613611860825 email: fengjfmail@163.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06321133 id: 5402589 briefTitle: High Flow Nasal Cannula Weaning in Acute Bronchiolitis overallStatus: RECRUITING date: 2024-02-13 date: 2026-12-31 date: 2026-12-31 date: 2024-03-20 date: 2024-03-20 name: Kuopio University Hospital class: OTHER name: Central Finland Hospital District name: Mikkeli Central Hospital name: Siun sote briefSummary: The goal of this clinical study is to compared two different strategies to end high flow nasal cannula treatment in acute bronchiolitis. This study compared the immediate ending of high flow treatment to weaning strategy, in which the flow rate is gradually decreased. The aim is to assess if the immediate ending shortens the hospitalization time and whether it is a safe strategy. conditions: Acute Bronchiolitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: High flow nasal cannula immediate ending name: High flow nasal cannula weaning measure: Hospitalization time from randomization measure: Treatment failures measure: Readmission rate measure: Overall hospitalization time sex: ALL minimumAge: 0 Months maximumAge: 12 Months stdAges: CHILD facility: Siun Sote status: RECRUITING city: Joensuu country: Finland name: Paula Widgren, MD, PhD role: CONTACT phone: 0045813 330 8285 email: paula.widgren@siunsote.fi lat: 62.60118 lon: 29.76316 facility: Central Finland Hospital District status: RECRUITING city: Jyväskylä country: Finland name: Milla Pitkänen, MD role: CONTACT phone: 0035814 2691811 email: milla.pitkanen@hyvaks.fi lat: 62.24147 lon: 25.72088 facility: Kuopio University Hospital status: RECRUITING city: Kuopio country: Finland name: Ilari Kuitunen, MD, PhD role: CONTACT phone: +358447174910 email: ilari.kuitunen@uef.fi name: Marjo Renko, Professor role: CONTACT name: Katri Backman, MD, PhD role: SUB_INVESTIGATOR name: Miika Arvonen, MD, PhD role: SUB_INVESTIGATOR lat: 62.89238 lon: 27.67703 facility: Mikkeli Central Hospital status: RECRUITING city: Mikkeli country: Finland name: Nicole Weisshoff, MD role: CONTACT phone: 0035815 3511 email: nicole.weisshoff@etelasavonha.fi lat: 61.68857 lon: 27.27227 hasResults: False
nctId: NCT06321120 id: 0749-21-HMO-CTIL briefTitle: Using Chronobiology to Improve Lenvatinib Efficacy overallStatus: RECRUITING date: 2023-03-01 date: 2024-04 date: 2024-06 date: 2024-03-20 date: 2024-03-20 name: Hadassah Medical Organization class: OTHER briefSummary: The goal of this proof-of-concept clinical trial is to assess the efficacy and safety of chronobiology implementation into lenvatinib treatment regimens of thyroid cancer patients, via a mobile application.
Participants will use a mobile application to follow variability-based physician approved drug administration schedules. conditions: Lenvatinib Treatment studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: An open-labeled, prospective, single-center proof-of-concept clinical trial lasting 14 weeks was conducted to investigate the impact of an algorithm-based regimen on enhancing lenvatinib effectiveness. primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: variability-based lenvatinib regimen measure: disease progression/ tumor response measure: Adverse effects occurrence sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hadassah Medical Organization status: RECRUITING city: Jerusalem zip: 91120 country: Israel name: Hadas Lemberg, PhD role: CONTACT phone: +97226777572 email: lhadas@hadassah.org.il lat: 31.76904 lon: 35.21633 hasResults: False
nctId: NCT06321107 id: GenSci094-304 briefTitle: Long-term Follow-up Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference overallStatus: RECRUITING date: 2024-02-29 date: 2025-08-15 date: 2025-10-31 date: 2024-03-20 date: 2024-03-20 name: Changchun GeneScience Pharmaceutical Co., Ltd. class: INDUSTRY name: Sixth Affiliated Hospital, Sun Yat-sen University briefSummary: The purpose of this study is to evaluate the safety of a single injection of GenSci094 during Controlled Ovarian Stimulation up to 1 year old of the infants from previous studies. conditions: Infertility studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: OTHER count: 158 type: ESTIMATED measure: Summary of Pregnancy Outcome measure: neonatal birth outcomes measure: Infant development sex: FEMALE minimumAge: 20 Years maximumAge: 39 Years stdAges: ADULT facility: The Sixth Affiliated Hospital, Sun Yat-sen University Guangdong Gastrointestinal Hospital status: RECRUITING city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06321094 id: VERI-ACS briefTitle: Effect of Vericiguat on Endpoint Events in Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45% overallStatus: RECRUITING date: 2023-10-01 date: 2025-10-01 date: 2025-12-01 date: 2024-03-20 date: 2024-03-20 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: Investigators evaluate whether differences exsit in acute coronary syndrome（ACS） patients with ejection \<45% between participants who take vericiguat regularly and those who donot. conditions: Acute Coronary Syndrome conditions: Heart Failure With Reduced Ejection Fraction studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Vericiguat measure: a composite of death from cardiovascular causes or first hospitalization for heart failure measure: results of echocardiogram measure: the numerical value of NT-proBNP measure: level of procalcitonin measure: interleukin-6 level measure: life quality score sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: the First Affiliated Hospital of Nanjing Medical University status: RECRUITING city: Nanjing state: Jiangsu country: China name: Liansheng Wang, Doctor role: CONTACT phone: 85 25 68303830 email: drlswang@njmu.edu.cn lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06321081 id: 2023BJYYEC-428-02 briefTitle: ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC overallStatus: RECRUITING date: 2024-03-01 date: 2026-02-14 date: 2026-08-14 date: 2024-03-20 date: 2024-03-20 name: Beijing Hospital class: OTHER_GOV name: Bethune Charitable Foundation briefSummary: This is a non-profit phase II, open, clinical study of the combination of irinotecan plus cetuximab and envafolimab as a rechallenge regimen, in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients (according to liquid biopsy at baseline). Patients have been treated in front lines with irinotecan and cetuximab and had a clinical benefit (complete or partial response) from both of them, no matter whether they had treated by any PD-1 inhibitor before. conditions: RAS Mutation conditions: Metastatic Colorectal Cancer conditions: MSS studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: irinotecan, cetuximab, envafolimab measure: progression free survival measure: Overal survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Hospital status: RECRUITING city: Beijing state: Beijing zip: 100730 country: China name: Yingying Huang role: CONTACT phone: 86-10-85136715 email: yinghh@hotmail.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06321068 id: BAT-1308-003-CR briefTitle: BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer overallStatus: RECRUITING date: 2024-04-09 date: 2024-09 date: 2027-10 date: 2024-03-20 date: 2024-04-18 name: Bio-Thera Solutions class: INDUSTRY briefSummary: Phase II study: Safety and preliminary efficacy of BAT1308 combined with platinum-containing chemotherapy;Phase III study: Confirmatory safety and efficacy study of BAT1308 combined with platinum-containing chemotherapy for first-line treatment of advanced or recurrent mismatch repair protein-deficient (dMMR) endometrial carcinoma conditions: Endometrial Cancer studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 140 type: ESTIMATED name: carboplatin name: Paclitaxel name: Recombinant humanized anti-PD-1 monoclonal antibody injection measure: vital signs measure: Physical examination measure: Adverse events measure: Clinical laboratory tests measure: Clinical auxiliary tests measure: Dose-limiting toxicity (DLT) measure: Progression Free Survival measure: Initial efficacy measure: Pharmacokinetic measure: Pharmacokinetic measure: Pharmacokinetic measure: Pharmacokinetic measure: Immunogenicity measure: Immunogenicity sex: FEMALE minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Affiliated Cancer Hospital of Chongqing University status: RECRUITING city: Chongqing state: Chongqing country: China name: Qi Zhou role: CONTACT phone: 86-13708384529 email: qizhou9128@163.com lat: 29.56278 lon: 106.55278 hasResults: False
nctId: NCT06321055 id: 22533 briefTitle: An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2024-04-28 date: 2024-04-28 date: 2024-03-20 date: 2024-03-20 name: Bayer class: INDUSTRY briefSummary: This is an observational study in which data already collected from people with advanced gastrointestinal stromal tumors are studied.
The study drug, regorafenib, is already approved for doctors to prescribe to people with GIST. Regorafenib works by blocking certain proteins that cause the growth of cancer cells. Regorafenib is recommended as the third choice of treatment for patients after imatinib and sunitinib have stopped working or have caused side effects that are too severe to continue the treatment. In addition, it is also the recommended first choice of treatment in people with GIST who had low levels of protein called succinate dehydrogenase (SDH) protein. This condition is called SDHdeficient GIST. However, doctors might sometimes give it in a different order. To better understand the treatment patterns with regorafenib for GIST, more knowledge is needed about its use in the real world.
In this study, only available data are collected. No visits or tests are required as part of this study. conditions: Advanced Gastrointestinal Stromal Tumor studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 136 type: ESTIMATED name: Regorafenib (Stivarga, BAY73-4506) measure: Duration of Therapy (DOT) on regorafenib measure: Time to Next Therapy (TTNT) therapy after regorafenib measure: Number of the guideline-listed medications other than regorafenib measure: Descriptive analysis of baseline demographic measure: Descriptive analysis of clinical characteristics measure: Number of patients with evidence of any metastasis on or after the index date during the follow-up period. measure: Number of patients with evidence of surgery on or after the index date during the follow-up period using Current Procedural Terminology (CPT) codes and International Classification of Disease 9/10 Procedure codes (ICD-PC). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bayer city: Whippany state: New Jersey zip: 07981 country: United States lat: 40.82454 lon: -74.4171 hasResults: False